This page provides study documentation for A214. For description of the specimen results, see Specimen Results Description (open to public). Data sets of the specimen results are included in the existing WHI datasets located on the WHI Data on this site (sign in and a completed Data Distribution Agreement are required; see details on the Data site).
Investigator Names and Contact Information
Charles S. Fuchs, MD, MPH
Each year, 30,000 Americans die of cancer of the pancreas, making pancreatic cancer the fourth most common cause of cancer-related mortality. Nonetheless, relatively little is known about the pathogenesis and epidemiology of this malignancy. In a ongoing grant from the National Cancer Institute (Fuchs, PI, R01CA86102, WHI AS146), we are conducting analyses in pancreatic cancer using DNA and plasma from participants in the Women’s Health Initiative (WHI) in conjunction with specimens from the Nurses’ Health Study (NHS), Health Professionals Follow-up Study (HPFS), Women’s Health Study (WHS) and the Physicians’ Health Study (PHS). We wish to extend our analyses in pancreatic cancer among participants in the WHI (and the other cohorts) for the purpose of a competitive renewal of this grant. Continued pooling of cases from the ongoing prospective cohort studies will allow a rigorous examination of this important cancer. Blood specimens will be analyzed using a matched, nested case-control design of projected cases through 2007 to evaluate hypotheses focusing on mechanisms of pancreatic cancer pathogenesis. Using these resources, we propose to examine energy balance, insulin and insulin-like growth factor signaling, inflammation and H. pylori, and retinol and vitamin D-related pathways. By better understanding mechanisms, inter-relations between factors acting in similar pathways, and genetic variation, we can identify recommendations at reducing the incidence and mortality from this highly fatal malignancy.